3240-35-5|4-Formylbenzenesulfonamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 3240-35-5 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 3240-35-5 ]

CAS No. :	3240-35-5
Formula :	C₇H₇NO₃S
M.W :	185.20
SMILES Code :	O=S(C1=CC=C(C=O)C=C1)(N)=O
MDL No. :	MFCD03196508
Boiling Point :	No data available
InChI Key :	PCPUKVSTMLHXQF-UHFFFAOYSA-N
Pubchem ID :	151088

Safety of [ 3240-35-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of [ 3240-35-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 3240-35-5 ]

[ 3240-35-5 ] Synthesis Path-Downstream 1~36

1
[ 3119-02-6 ]
[ 3240-35-5 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1013 - 1015.
[2]Journal of the Chemical Society,1948,p. 601.
[3]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 2697 - 2706.
[4]Tetrahedron Letters,2010,vol. 51,p. 3645 - 3648.

2
[ 99856-72-1 ]
[ 3240-35-5 ]

Yield	Reaction Conditions	Operation in experiment
12%	With sulfuric acid; In ethanol; water; for 2h;Reflux;	EXAMPLE 5. Preparation of 13. Concentrated sulfuric acid (7 mL) was added dropwise to the mixture of acetic anhydride (80 niL) and acetic acid (40 mL). The mixture was cooled with ice bath. 4- Methylbenzenesulfonamide 1 1 (12 g, 70 mmol) was added and the reaction temperature was maintained beneath 5 C. Chromium oxide (8g, 80 mmol) was added in batches. Then the reaction mixture was stirred for 4 h at 5-10 C, then the solution was poured into ice water (500 mL). The aqueous solution was extracted with DCM (3* 100 mL). The combined organic phase was washed with brine, dried over anhydrous sodium sulphate and concentrated to give (4-sulfamoylphenyl)methylene diacetate 12 as a yellow oil. The yellow oil which was achieved in the last step was dissolved in ethanol (10 mL). Water ( 10 mL) and concentrated sulfuric acid (2 mL) was added. The reaction mixture was heated to reflux and stirred for 2 h. Solvent was concentrated and the residue was diluted with water (50 mL). The aqueous solution was extracted with ethyl acetate (2*20 mL). The combined organic phase was dried over sodium sulphate and concentrated. The residue was purified by column on silica gel (eluent: Hexane/EA 3: 1 to 1 : 1 ) to afford 13 as a white solid (1.5 g, 12% yield). FontWeight="Bold" FontSize="10" H NMR (400 MHz, DMSO) δ 10.09 (s, 1 H), 8.10 (d, J - 8.3 Hz, 2H), 8.03 (d, J - 8.3 Hz, 2H), 7.59 (s, 2H).
		Example I; Preparation of the sodium salt of N-methoxycarbonyl-4-(4,5-dihydro-l-phenyl-3-trifluoromethyl-lH-pyrazole-S-yl)benzenesulphonamide (Compound 31 of Table 1); (a) and (b) 4-Formil benzenesulphonamide; AcO OAcCrO3/H2SO4-----------»•(a)H2S04 /EtOH(b)*"o=s=oo=s=oo=s=oNH,Acetic anhydride (400 ml) is placed in a 1000 ml flask, cooled to -10C, CrO3 (70g, 0.7 moles) is added and stirred for In at 0C.In another flask p-toluenesulphonamide (40g, 234 mmoles) is suspended in acetic anhydride (350 ml) , cooled to -10C and H2SO<i (60 ml) is added dropwise and slowly, since the reaction is quite exothermic. The solid is dissolved entirely. It is left for 15 min at 0C and the solution of the oxidising mixture, prepared independently as indicated above, is added to it. Once the addition is finished it is stirred for 2.5 h at 0C. It is then poured onto ice-water (approximate ratio of 7:1, 4 litres) and it is stirred overnight. The resulting solution is extracted with AcOEt, the organic solution is washed with water, 'dried over sodium sulphate, filtered and evaporated to dryness.To the resulting pasty mixture, ethanol (130 ml), water (40 ml) and H2S04 (8 ml) are added, and it is heated at reflux for 2.5 h. It is cooled, solvent is eliminated in a rotavapor and the residue is separated between AcOEt and water. The organic phase is washed with a 5% potassium carbonate solution and water. Once the organic solution is dried and evaporated, there remain 13.4 g (31%) of crude, cream-coloured solid, which is used without purifying in the next stage.IR (KBr, cm'1) : 3357, 3244, 1701, 1337, 1172:H NMR (de-DMSO, 5 ppm) : 7.57 (s, 2H) , 8.0 (d,J=8.2Hz, 2H), 8.1 (d, J=8.2Hz, 2H) , 10.1 (s, IH)

References: [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 7349 - 7353.
[2]Patent: WO2014/190015,2014,A1 .Location in patent: Page/Page column 22-24.
[3]Sb. Statei Obshch. Khim.,1953,p. 527,529.
Chem.Abstr.,1955,p. 932.
[4]Sb. Statei Obshch. Khim.,1953,p. 527,529.
Chem.Abstr.,1955,p. 932.
[5]Patent: WO2006/11005,2006,A1 .Location in patent: Page/Page column 23-24.

3
[ 3240-35-5 ]
[ 108-24-7 ]
[ 796072-77-0 ]

References: [1]European Journal of Organic Chemistry,2013,p. 5381 - 5386.
[2]Takeda Kenkyusho Nenpo,1954,vol. 13,p. 31.
Chem.Abstr.,1956,p. 218.

4
[ 70-55-3 ]
[ 3240-35-5 ]

References: [1]Biochemical Journal,1917,vol. 11,p. 84.
[2]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 7349 - 7353.
[3]Patent: WO2013/149996,2013,A1 .
[4]Patent: WO2014/190015,2014,A1 .

5
[ 3240-35-5 ]
[ 65-85-0 ]
[ 179056-87-2 ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 15 - 30.

6
[ 179057-35-3 ]
[ 3240-35-5 ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 15 - 30.

7
[ 3240-35-5 ]
[ 426842-08-2 ]
4-[4,6-dimethoxy-7-(1-methyl-piperidin-4-yl)-3-oxo-3<i>H</i>-benzofuran-2-ylidenemethyl]-benzenesulfonamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1741 - 1747.

8
[ 3240-35-5 ]
[ 67472-44-0 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1013 - 1015.

9
[ 3240-35-5 ]
[ 4047-24-9 ]
(E)-4-[3-(2-benzyloxy-6-hydroxyphenyl)-3-oxopropene-1-yl]benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 104 - 111.

10
[ 3240-35-5 ]
[ 919092-53-8 ]
(E)-4-[3-(2-cyclohexylmethoxy-6-hydroxyphenyl)-3-oxopropene-1-yl]benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 104 - 111.

11
[ 3240-35-5 ]
[ 915364-11-3 ]
4-([3-cyano-4-(cyclopentylamino)quinolin-6-yl]amino}methyl)benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 6425 - 6442.

12
[ 3240-35-5 ]
[ 948587-48-2 ]
4-([4-(tert-butylamino)-3-cyanoquinolin-6-yl]amino}methyl)benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 6425 - 6442.

13
[ 3240-35-5 ]
[ 40724-47-8 ]